Similar articles

• Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports.

  Elston J, Taylor RS. Elston J, et al. Int J Technol Assess Health Care. 2009 Jan;25(1):6-13. doi: 10.1017/S0266462309090023. Int J Technol Assess Health Care. 2009. PMID: 19126246
• Use of Surrogate Outcomes in Nephrology Research.

  Samuels J. Samuels J. Adv Chronic Kidney Dis. 2016 Nov;23(6):363-366. doi: 10.1053/j.ackd.2016.11.008. Adv Chronic Kidney Dis. 2016. PMID: 28115079 Review.
• Biomarkers and surrogates in clinical studies.

  Rigatto C, Barrett BJ. Rigatto C, et al. Methods Mol Biol. 2009;473:137-54. doi: 10.1007/978-1-59745-385-1_8. Methods Mol Biol. 2009. PMID: 19160736 Review.
• Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.

  Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO 3rd, Hughes M, Altman D, Buyse M, Galbraith S, Wells G. Lassere MN, et al. J Rheumatol. 2007 Mar;34(3):607-15. J Rheumatol. 2007. PMID: 17343307
• What are surrogate outcome measures and why do they fail in clinical research?

  Johnston K. Johnston K. Neuroepidemiology. 1999;18(4):167-73. doi: 10.1159/000026208. Neuroepidemiology. 1999. PMID: 10364717 Review.